LEAMINGTON, Ontario, June 29, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer packaged goods that inspires and empowers people around the world to live their best lives, today announced that its dedicated medical cannabis division, Tilray Medical, has expanded its medical cannabis offering in the UK. Tilray Medical now offers the broadest portfolio of cannabis flowers in the UK market today, including a differentiated range of high concentration THC products grown in its EU-GMP certified facility in Portugal.
Denise Faltischek, Tilray’s Chief Strategy Officer and Head of International Business, said: “The demand for medical cannabis in the UK is growing rapidly. We take incredible pride in providing patients in the UK with consistent, high quality medical cannabis products that they can rely on and are accessible to them. »
Tilray Medical now offers an extensive selection of medical cannabis products, including a market-leading portfolio of cannabis flowers featuring THC levels ranging from 10-25% and offering a range of different ratios1. Tilray Medical’s UK portfolio is underpinned by a wide range of cultivars, each with a unique cannabinoid and terpene profile, which have been selected to ensure patients can receive both the highest quality product and the utmost consistency when it comes to providing their medicinal cannabis products. By offering such a wide range of cannabis flower products in the UK, Tilray Medical hopes to expand the range of treatment options available to patients and to ensure that prescribers and patients are provided with a safe and reliable as they embark on their medical cannabis journey.
In the UK, patients can obtain prescriptions for medical cannabis through their specialist doctor. Tilray Medical supplies the UK and the rest of our international business with EU-GMP certified medical cannabis from our state-of-the-art facilities in Portugal, providing patients with safe and reliable access to high quality medical cannabis.
For further information on Tilray’s medical cannabis and the above cultivars available in the UK, please visit: https://tilraymedical.co.uk/
About Tilray Medical
With safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast and Symbios, Tilray Medical is dedicated to transforming the lives and promoting the dignity of patients in need of these products. After becoming one of the first companies to be a licensed producer of medical cannabis in Canada, Tilray built the first EU-GMP certified cannabis production facilities in Europe, first in Portugal and then in Germany. Tilray Medical is today one of the largest providers of medical cannabis brands to patients, doctors, hospitals, pharmacies, researchers and governments, in 20 countries and on five continents.
For further information on Tilray Medical, please visit Tilray Medical Canada, Tilray Medical Australia, Tilray Medical Australia-New Zealand and Tilray Medical Europe
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) is a leading global cannabis and consumer packaged goods company operating in Canada, the United States, Europe, Australia and Latin America, that changes people’s lives for the better – one person at a time. Tilray Brands accomplishes this mission by inspiring and empowering people around the world to live their best lives and by providing access to products that meet the needs of their mind, body and soul while invoking good. -be. Patients and consumers trust Tilray Brands to deliver a cultured experience and good health and well-being through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation and distribution, Tilray’s unparalleled production platform supports over 20 brands in over 20 countries, including complete cannabis offerings, hemp edibles and craft drinks.
For more information on how we’re opening a world of wellness, visit www.Tilray.com and follow @Tilray on Instagram and Twitter.
Forward-looking statements
Certain statements contained in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act. of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be subject to the “safe harbor rule” created by those sections and by other applicable laws. The terms “predict”, “future”, “should”, “could”, “enable”, “potential”, “envisage”, “believe”, “anticipate”, “estimate”, “plan”, “expect to “”intend”, “may”, “plan”, “should” and the negative forms of these terms or similar expressions are used to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. Certain material factors, estimates, objectives, projections or assumptions have been used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our current intentions, beliefs, projections, prospects, analyzes or expectations regarding, among other things, expectations regarding the performance and scale of the Company, including Tilray Medical, and the ability of the Company to expand its offering to patients worldwide, including through Tilray Medical. Many factors could cause actual results, performance or achievements to differ materially from any forward-looking statements, and other risks and uncertainties not currently known to the Company or which the Company considers to be immaterial could also cause the results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see Tilray’s most recently filed Annual Information Form and Tilray’s Annual Report on Form 10-K (and other periodic reports filed with the SEC) established with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication, and the Company undertakes no obligation to update them publicly to reflect new information, subsequent events or otherwise, except as required by applicable laws. securities require it.
For further information:
Berrin Noorata
Media, Tilray Global: [email protected]
Investors
Raphael Gross
203-682-8253
[email protected]
________________________________
1Actual cannabinoid content may vary. Tilray products are manufactured according to EU-GMP standards and comply with product specifications in accordance with European pharmaceutical standards.
